All Eli Lilly articles – Page 2
-
FeaturePharma queues up for checkpoint inhibitor collaborations
Combinations of different firms’ drugs seek to reap immuno-oncology’s benefits
-
Business
Judge slashes fines in drug safety case
Takeda and Eli Lilly’s $9 billion damages in diabetes trial reduced to $38 million
-
BusinessEMA wrangles restrain trial data progress
Attempts to balance industry and research interests on transparency draw suggestions of improper collusion
-
Business
Lilly protests $450m Brazilian fine
Firm says chemicals employees were allegedly exposed to were never used at site
-
Business$25bn-plus trade sharpens pharma giants’ focus
Novartis’ asset swaps with GSK and Eli Lilly are the latest steps in an ongoing streamlining process
-
BusinessMissing safety risk emails draw $9bn Actos fine
Judge finds absence of Takeda documentation in bladder cancer case ‘disturbing’
-
Business
Lilly wins cancer drug patent dispute
Alimta patent will last until 2022 after US court rules in Lilly’s favour
-
-
BusinessLilly freezes pay as patent cliff looms
Drugmaker targets $400 million savings as two key patents near expiry
-
Business
NHS to offer breast cancer prevention drugs
Five-year course of tamoxifen or raloxifene recommended for high risk women
-
Business
Patent woes lead to sharp sales losses
Bristol-Myers Squibb, AstraZeneca and Eli Lilly have all suffered loss of exclusivity for key drugs
-
Business
Alzheimer's drug flops in Phase III
Solanezumab from Eli Lilly missed the cognitive and functional primary endpoints of the trials
- Previous Page
- Page1
- Page2
- Next Page